Männedorf, Switzerland, January9, 2023 - The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences this week:
41st Annual J.P. Morgan Healthcare Conference, San Francisco
Date: 11 January 2023
Presentation: 5:15 pm PST
A replay of the webcast will be available after the presentation and will remain available for 30 days.
Baader Helvea Swiss Equities Conference, Bad Ragaz
Date: 12 January 2023
Presentation: 12:00 pm CET
Presenter: Tania Micki, CFO, Tecan
Not webcasted
Octavian Seminar 2023, Flims
Date: 13 January 2023
Participants: Tania Micki, CFO, Tecan & Martin Brändle, SVP, Corp. Comm. & IR, Tecan
Not webcasted
About Tecan
Tecan (www.tecan.com) improves people's lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2021, Tecan generated sales of CHF 947 million (USD 1,041 million; EUR 877 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Tecan Group
Martin Braendle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com
Attachment
- Press Release (https://ml-eu.globenewswire.com/Resource/Download/8419c53f-e5c4-46fc-b96d-fc3bfcd150ee)
